Human OX40L–CAR-T regs target activated antigen-presenting cells and control T cell alloreactivity
Science Translational Medicine · 16.10.2024 · 16 (769)
DOI: 10.1126/scitranslmed.adj9331 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Translational Medicine, erschienen am 16.10.2024. Verfasst von Xianliang Rui und 11 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology/Oncology, Boston Children's Hospital, Boston, MA 02115, USA. Hauptthemen laut MEDLINE: T-Lymphocytes, Regulatory, OX40 Ligand, Antigen-Presenting Cells. Die Arbeit wurde bisher 49-mal zitiert (Crossref) und nennt 80 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, NCI NIH HHS, NIAID NIH HHS.
Abstract (Originalsprache)
Regulatory T cells (T regs ) make major contributions to immune homeostasis. Because T reg dysfunction can lead to both allo- and autoimmunity, there is interest in correcting these disorders through T reg adoptive transfer. Two of the central challenges in clinically deploying T reg cellular therapies are ensuring phenotypic stability and maximizing potency. Here, we describe an approach to address both issues through the creation of OX40 ligand (OX40L)–specific chimeric antigen receptor (CAR)–T regs under the control of a synthetic forkhead box P3 ( FOXP3 ) promoter. The creation of these CAR-T regs enabled selective T reg stimulation by engagement of OX40L, a key activation antigen in alloimmunity, including both graft-versus-host disease and solid organ transplant rejection, and autoimmunity, including rheumatoid arthritis, systemic sclerosis, and systemic lupus erythematosus. We demonstrated that OX40L–CAR-T regs were robustly activated in the presence of OX40L-expressing cells, leading to up-regulation of T reg suppressive proteins without induction of proinflammatory cytokine production. Compared with control T regs , OX40L–CAR-T regs more potently suppressed alloreactive T cell proliferation in vitro and were directly inhibitory toward activated monocyte-derived dendritic cells (DCs). We identified trogocytosis as one of the central mechanisms by which these CAR-T regs effectively decrease extracellular display of OX40L, resulting in decreased DC stimulatory capacity. OX40L–CAR-T regs demonstrated an enhanced ability to control xenogeneic graft-versus-host disease compared with control T regs without abolishing the graft-versus-leukemia effect. These results suggest that OX40L–CAR-T regs may have wide applicability as a potent cellular therapy to control both allo- and autoimmune diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Hematology/Oncology, Boston Children's Hospital, Boston, MA 02115, USA.
- Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
- Harvard Medical School, Boston, MA 02115, USA.
- Division of Immunology, Boston Children's Hospital, Boston, MA 02215, USA.
- University of British Columbia, Vancouver, BC V6T 1Z1, Canada.
- Division of Pediatric Blood and Marrow Transplant and Cellular Therapy, University of Minnesota, Minneapolis, MN 55455, USA.
ORCID-Profile: Xianliang Rui, Francesca Alvarez Calderon, Holly Wobma, Ulrike Gerdemann, Alexandre Albanese, Connor McGuckin, Kisa Naqvi, Bruce R Blazar, Victor Tkachev, Leslie S Kean
Förderung
- NHLBI NIH HHS
- NCI NIH HHS
- NIAID NIH HHS
Zitieren
APA
Rui, X., Alvarez Calderon, F., Wobma, H., Gerdemann, U., Albanese, A., Cagnin, L., McGuckin, C., Michaelis, K. A., Naqvi, K., Blazar, B. R., Tkachev, V., & Kean, L. S. (2024). Human OX40L–CAR-T regs target activated antigen-presenting cells and control T cell alloreactivity. Science Translational Medicine, 16(769). https://doi.org/10.1126/scitranslmed.adj9331
Vancouver
Rui X, Alvarez Calderon F, Wobma H, Gerdemann U, Albanese A, Cagnin L, et al. Human OX40L–CAR-T regs target activated antigen-presenting cells and control T cell alloreactivity. Science Translational Medicine. 2024;16(769). doi:10.1126/scitranslmed.adj9331
BibTeX
@article{Rui2024,
author = {Rui, Xianliang and Alvarez Calderon, Francesca and Wobma, Holly and Gerdemann, Ulrike and Albanese, Alexandre and Cagnin, Lorenzo and McGuckin, Connor and Michaelis, Katherine A and Naqvi, Kisa and Blazar, Bruce R and Tkachev, Victor and Kean, Leslie S},
title = {Human OX40L–CAR-T regs target activated antigen-presenting cells and control T cell alloreactivity},
journal = {Science Translational Medicine},
year = {2024},
volume = {16},
number = {769},
doi = {10.1126/scitranslmed.adj9331}
}
EUVIMED